Shots: The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF for the treatment of multiple […]readmore
Shots: The designation is based on the ongoing P-III DIALIZE-Outcomes trial to evaluate the effect of Lokelma on arrhythmia-related CV outcomes in patients with chronic hemodialysis with recurrent HK at […]readmore
Shots: The companies collaborated for CDx development of tepotinib in mainland China. The CDx test is based on Burning Rock’s OncoCompass target which is a self-developed NGS-based liquid biopsy solution […]readmore
Shots: Under the existing collaboration agreement, Takeda has exercised an option to co-develop and co-commercialize DNL593 (PTV: PGRN) as brain-penetrant progranulin replacement therapy for the treatment of FTD-GRN In Jan […]readmore
In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment of Neurodegenerative Diseases Shots: The […]readmore
Shots: The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in non-hospitalized adult patients with COVID-19 with 1 risk factor associated with poor disease outcomes & symptom onset within 5 days […]readmore
Shots: The approval is based on KEEPsAKE-1 & 2 studies to evaluate Skyrizi (150mg) vs PBO in patients with active PsA who had an inadequate response or were intolerant to […]readmore
Shots: The approval is based on the data from PK bridging studies and P-III EVOLVE-MS-2 study to evaluate the GI tolerability of Vumerity vs Tecfidera in patients with relapsing-remitting MS […]readmore
Shots: The P-III trial evaluates arpraziquantel in patients aged 3mos. to 6yrs. with schistosomiasis who are infected with S. mansoni or S. haematobium The trial has met its 1EPs i.e., […]readmore
Shots: The companies launch Semglee and Insulin Glargine as interchangeable biosimilars products to improve patients’ access with type 1 & 2 diabetes. Biocon and Viatris have co-developed both biosimilars products […]readmore